PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsVolanesorsen
Volanesorsen
Waylivra (volanesorsen) is an oligonucleotide pharmaceutical. Volanesorsen was first approved as Waylivra on 2019-05-03. It has been approved in Europe to treat hyperlipoproteinemia type i.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
acne free blackhead removing scrub 2 salicylic acid with charcoalC2002632024-06-19
aha glycolic acid foam cleanser (sulfate-free)- 7.5 ozC2002632024-12-16
clear days aheadC2002632024-11-19
lactic acid free for sportswoman synergyOTC monograph not final2017-01-01
lactic acid free m synergyOTC monograph not final2016-10-24
oil free acne scrubOTC monograph final2010-07-08
peach slices 3 step acne starter kitC2002632024-08-14
premasol - sulfite-free (amino acid)ANDA2022-08-04
walgreens oil-free acne washC2002632024-06-03
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
C10: Lipid modifying agents
C10A: Lipid modifying agents, plain
C10AX: Other lipid modifying agents in atc
C10AX18: Volanesorsen
HCPCS
No data
Clinical
No data
Drug
General
Drug common nameVolanesorsen
INNvolanesorsen
Description
Volanesorsen, sold under the brand name Waylivra, is a triglyceride-reducing drug. It is a second-generation 2'-O-methoxyethyl (2'-MOE) chimeric antisense therapeutic oligonucleotide (ASO) that targets the messenger RNA for apolipoprotein C3 (apo-CIII).
Classification
Oligonucleotide
Drug classantisense oligonucleotides
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL3544994
ChEBI ID
PubChem CID122409770
DrugBankDB15067
UNII ID2O4BE0K238 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
Waylivra Ionis Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use